T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease

Thomas E. Lew; Edward R. Scheffer Cliff; Michael Dickinson; Constantine S. Tam; John F. Seymour; Piers Blombery; Ashish Bajel; David Ritchie; Amit Khot

doi:10.1038/s41409-021-01418-3

Related publications

Article2021

T-Cell Replete Allogeneic Stem Cell Transplant Is an Effective Treatment Option for Patients with TP53 mutated Mantle Cell Lymphoma

Edward R. Scheffer Cliff, Thomas E. Lew, Piers Blombery, Michael Dickinson, Constantine S. Tam, John F. Seymour, Ashish Bajel, David Ritchie, Amit Khot

Article2023

Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in <i>TP53</i> -mutated disease

Thomas E. Lew, Edward R. Scheffer Cliff, Michael Dickinson, Constantine S. Tam, John F. Seymour, Piers Blombery, Ashish Bajel, David Ritchie, Amit Khot

Article2023

Treatment approaches for patients with TP53-mutated mantle cell lymphoma

Thomas E. Lew, Adrian Minson, Michael Dickinson, Sasanka M. Handunnetti, Piers Blombery, Amit Khot, Mary Ann Anderson, David Ritchie, Constantine S. Tam, John F. Seymour

Article2016

Interventions for the Prophylaxis and Treatment of Graft versus Host Disease in Patients Undergoing Allogeneic Stem Cell Transplant (2017).

Dianna Wolfe, Brian Hutton, David Moher, Fatemeh Yazdi, Christopher Bredeson, Natasha Kekre, David Allan

Article2003

73 The ottawa 10-year experience in allogeneic stem cell transplantation for follicular lymphoma

Mitchell Sabloff, Sheryl McDiarmid, Isabelle Bence‐Bruckler, Harold Atkins, Christopher Bredeson, H. S. Hopkins, P. Genest, George Perry, Lothar Huebsch